抗癌药物与他汀类药物联合使用

Mohammad Adnan, K. Mohammad, Mohammad Emdad Hossain Manik
{"title":"抗癌药物与他汀类药物联合使用","authors":"Mohammad Adnan, K. Mohammad, Mohammad Emdad Hossain Manik","doi":"10.4172/JBB.1000345","DOIUrl":null,"url":null,"abstract":"Statins are 3-Hydroxy-3-methylgutaryl CoA (HMG CoA) reductase inhibitors and mainly used in cardiovascular diseases. However, they are also widely known for their anticancer activities mediated by antiproliferative, proapoptotic, anti-invasive, and radio sensitizing properties. They are tested alone in several clinical trials for their anticancer activity and the response in not satisfactory due to high dose requirements in humans. Tumor inhibitory concentration of statins is 10-100 μM for different cancer cell lines when tested in vitro. But statins can cause anorexia and death in some individuals if concentration is reached to 20-25 μM in serum. So, there is high risk factor. To avoid these unwanted harmful effects, we can give statins in combination with other chemotherapeutic drugs for synergism. It will reduce the concentration of statins in dosage, and can avoid unwanted toxic effects. When used along with the other chemo therapeutic agents like prenylation inhibitors, NSAIDS and standard chemotherapeutic agents, they have shown much better results at lower doses with little or no toxicity.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"19 1","pages":"463-466"},"PeriodicalIF":0.0000,"publicationDate":"2017-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":"{\"title\":\"Anticancer Agents in Combination with Statins\",\"authors\":\"Mohammad Adnan, K. Mohammad, Mohammad Emdad Hossain Manik\",\"doi\":\"10.4172/JBB.1000345\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Statins are 3-Hydroxy-3-methylgutaryl CoA (HMG CoA) reductase inhibitors and mainly used in cardiovascular diseases. However, they are also widely known for their anticancer activities mediated by antiproliferative, proapoptotic, anti-invasive, and radio sensitizing properties. They are tested alone in several clinical trials for their anticancer activity and the response in not satisfactory due to high dose requirements in humans. Tumor inhibitory concentration of statins is 10-100 μM for different cancer cell lines when tested in vitro. But statins can cause anorexia and death in some individuals if concentration is reached to 20-25 μM in serum. So, there is high risk factor. To avoid these unwanted harmful effects, we can give statins in combination with other chemotherapeutic drugs for synergism. It will reduce the concentration of statins in dosage, and can avoid unwanted toxic effects. When used along with the other chemo therapeutic agents like prenylation inhibitors, NSAIDS and standard chemotherapeutic agents, they have shown much better results at lower doses with little or no toxicity.\",\"PeriodicalId\":15184,\"journal\":{\"name\":\"Journal of Bioequivalence & Bioavailability\",\"volume\":\"19 1\",\"pages\":\"463-466\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-07-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bioequivalence & Bioavailability\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/JBB.1000345\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bioequivalence & Bioavailability","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/JBB.1000345","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

摘要

他汀类药物是3-羟基-3-甲基gutaryl CoA (HMG CoA)还原酶抑制剂,主要用于心血管疾病。然而,它们也因其抗增殖、促凋亡、抗侵袭和放射性致敏特性介导的抗癌活性而广为人知。它们在几个临床试验中单独测试了它们的抗癌活性,但由于对人体的高剂量要求,反应并不令人满意。他汀类药物体外抑瘤浓度为10 ~ 100 μM。但当他汀类药物在血清中的浓度达到20 ~ 25 μM时,可引起部分个体的厌食和死亡。所以,这是一个高风险因素。为了避免这些不必要的有害影响,我们可以将他汀类药物与其他化疗药物联合使用以实现协同作用。它将降低他汀类药物的剂量浓度,并可以避免不必要的毒性作用。当与其他化疗药物一起使用时,如戊酰化抑制剂,非甾体抗炎药和标准化疗药物,它们在低剂量下显示出更好的效果,几乎没有毒性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Anticancer Agents in Combination with Statins
Statins are 3-Hydroxy-3-methylgutaryl CoA (HMG CoA) reductase inhibitors and mainly used in cardiovascular diseases. However, they are also widely known for their anticancer activities mediated by antiproliferative, proapoptotic, anti-invasive, and radio sensitizing properties. They are tested alone in several clinical trials for their anticancer activity and the response in not satisfactory due to high dose requirements in humans. Tumor inhibitory concentration of statins is 10-100 μM for different cancer cell lines when tested in vitro. But statins can cause anorexia and death in some individuals if concentration is reached to 20-25 μM in serum. So, there is high risk factor. To avoid these unwanted harmful effects, we can give statins in combination with other chemotherapeutic drugs for synergism. It will reduce the concentration of statins in dosage, and can avoid unwanted toxic effects. When used along with the other chemo therapeutic agents like prenylation inhibitors, NSAIDS and standard chemotherapeutic agents, they have shown much better results at lower doses with little or no toxicity.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Future Outlook for Biosafety and Biotechnology Effect of Fatty Acids on Bioavailability Clinical Trials of COVID-19 in China Anticipation of Castor Industry and Bottle Scruff Deviation Range to Address Genuine Bioavailability
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1